四環醫藥(0460.HK)一度大漲超15%
格隆匯1月29日丨四環醫藥盤中拉昇一度大漲15.12%至1.98港元,目前漲幅約10%,市值179億港元。公司午間公吿,集團已完成對深圳市邁步機器人科技有限公司“邁步機器人”的戰略投資,投後持股比例為2.65%。邁步機器人用於腦卒中導致下肢運動障礙的患者康復訓練的下肢外骨胳康復機器人已完成臨牀試驗,預計將於2021年上半年獲得II類醫療器械註冊證。這是繼集團的馬來酸桂呱齊特注射液(克林澳® )獲批用於治療急性缺血性腦卒中新適應症後,集團圍繞腦卒中治療產業鏈展開的又一戰略佈局。另外,公司還宣佈,子公司軒竹生物科技有限公司自主研發用以治療非酒精性脂肪肝炎(NASH)的XZP-5610項目藥品已於2021年1月成功獲國家藥品監督管理局批准開展臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.